201 related articles for article (PubMed ID: 23152132)
21. microRNA regulation of cell viability and drug sensitivity in lung cancer.
Du L; Pertsemlidis A
Expert Opin Biol Ther; 2012 Sep; 12(9):1221-39. PubMed ID: 22731874
[TBL] [Abstract][Full Text] [Related]
22. Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway.
Liu T; Zuo L; Guo D; Chai X; Xu J; Cui Z; Wang Z; Hou C
Biomed Pharmacother; 2019 Dec; 120():109483. PubMed ID: 31629252
[TBL] [Abstract][Full Text] [Related]
23. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
24. JNK pathway and relative transcriptional factor were involved in ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells.
Liu X; Sun Y; Yue L; Li S; Qi X; Zhao H; Yang Y; Zhang C; Yu H
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706758
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
26. The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer.
Wei X; Shen X; Ren Y; Hu W
Curr Pharm Des; 2018 Feb; 23(39):5983-5988. PubMed ID: 29046142
[TBL] [Abstract][Full Text] [Related]
27. Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells.
Xu N; Chen S; Liu Y; Li W; Liu Z; Bian X; Ling C; Jiang M
Cell Physiol Biochem; 2018; 48(5):2046-2060. PubMed ID: 30099455
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
Li Q; Yang Z; Chen M; Liu Y
Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
[TBL] [Abstract][Full Text] [Related]
29. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
30. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.
Hofmann HS; Bartling B; Simm A; Murray R; Aziz N; Hansen G; Silber RE; Burdach S
Oncol Rep; 2006 Sep; 16(3):587-95. PubMed ID: 16865260
[TBL] [Abstract][Full Text] [Related]
31. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128.
Wu N; Wu GC; Hu R; Li M; Feng H
Acta Pharmacol Sin; 2011 Mar; 32(3):345-53. PubMed ID: 21372826
[TBL] [Abstract][Full Text] [Related]
32. miRNAs, a potential target in the treatment of Non-Small-Cell Lung Carcinomas.
Malleter M; Jacquot C; Rousseau B; Tomasoni C; Juge M; Pineau A; Sakanian V; Roussakis C
Gene; 2012 Sep; 506(2):355-9. PubMed ID: 22732573
[TBL] [Abstract][Full Text] [Related]
33. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
34. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
Liu GW; Liu YH; Jiang GS; Ren WD
Hum Cell; 2018 Jul; 31(3):189-198. PubMed ID: 29582366
[TBL] [Abstract][Full Text] [Related]
35. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
Gao W; Yu Y; Cao H; Shen H; Li X; Pan S; Shu Y
Biomed Pharmacother; 2010 Jul; 64(6):399-408. PubMed ID: 20363096
[TBL] [Abstract][Full Text] [Related]
36. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Zhong M; Ma X; Sun C; Chen L
Chem Biol Interact; 2010 Mar; 184(3):431-8. PubMed ID: 20097187
[TBL] [Abstract][Full Text] [Related]
37. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G
Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335
[TBL] [Abstract][Full Text] [Related]
38. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells.
Liu J; Shimizu K; Yu H; Zhang C; Jin F; Kondo R
Fitoterapia; 2010 Oct; 81(7):902-5. PubMed ID: 20554003
[TBL] [Abstract][Full Text] [Related]
39. [Methylation of some miRNA genes is involved in the regulation of their target genes RAR-beta2 and NKIRAS1 expression in lung cancer].
Khodyrev DS; Pronina IV; Rykov SV; Beresneva EV; Fridman MV; Kazubskaia TP; Loginov VI; Braga ÉA
Mol Biol (Mosk); 2012; 46(5):773-85. PubMed ID: 23156677
[TBL] [Abstract][Full Text] [Related]
40. [Induction of differentiation by ginsenoside Rh2 in hepatocarcinoma cell SMMC-7721].
Zeng XL; Tu ZG
Ai Zheng; 2004 Aug; 23(8):879-84. PubMed ID: 15301707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
